title: Cross-reactivity between immune responses to Helicobacter bilis and Helicobacter pylori in a population in Thailand at high risk of developing cholangiocarcinoma.
abstract: Helicobacter bilis DNA has been detected in human tissue and is a candidate for etiologic investigations on the causes of hepatic and biliary tract diseases, but reliable serologic tests need to be developed in order to pursue such investigations. The scope of this study was to assess the specificity of two assays for H. bilis immune response allowing for H. pylori, and their cross-reactivity in a population in Thailand at high risk for cholangiocarcinoma. Plasma samples from 92 Thai volunteers were independently tested in two laboratories (Massachusetts Institute of Technology [MIT] and Lund). MIT performed three analyses of H. pylori and H. bilis based either on (i) outer membrane protein (OMP) with no preabsorption or on antigens derived from whole-cell sonicate before (ii) or after (iii) preabsorption with H. pylori sonicate protein. Lund used cell surface proteins from H. pylori and H. bilis as antigens. Testing for H. bilis was preabsorbed with a whole-cell lysate of H. pylori. More than 80% of the samples were positive for H. pylori in both laboratories. As tested by MIT, 58.7% (95% confidence interval, 47.9 to 68.9%) were positive for H. bilis by OMP and 44.5% (34.1 to 55.3%) were positive for H. bilis sonicate protein, but only 15.2% (8.6 to 24.2%) remained positive after preabsorption with H. pylori sonicate protein. Lund found 34.5% of the samples positive for H. bilis (22.0 to 41.0%), which was statistically compatible with all three MIT results. Serologic responses to OMPs of the two bacteria coincided in 66 and 45% of the samples in the MIT and Lund assays, respectively. We found high cross-reactivity between the immune responses to H. pylori and H. bilis antigens. More-specific H. bilis antigens need to be isolated to develop serologic tests suitable for epidemiological studies.
authors.affiliation: Descriptive Epidemiology Group, International Agency for Research on Cancer, 150 Cours Albert-Thomas, 69372 Lyon Cedex 03, France. paola.pisani@ceu.ox.ac.uk
authors.forename: Paola
authors.initials: P
authors.lastname: Pisani
authors.forename: Mark T
authors.initials: MT
authors.lastname: Whary
authors.forename: Ingrid
authors.initials: I
authors.lastname: Nilsson
authors.forename: Supannee
authors.initials: S
authors.lastname: Sriamporn
authors.forename: Torkel
authors.initials: T
authors.lastname: Wadström
authors.forename: James G
authors.initials: JG
authors.lastname: Fox
authors.forename: Asa
authors.initials: A
authors.lastname: Ljungh
authors.forename: David
authors.initials: D
authors.lastname: Forman
mesh_terms: D000328:Adult; D000368:Aged; D000907:Antibodies, Bacterial / Q000097:blood*; D000942:Antigens, Bacterial / Q000276:immunology; D001425:Bacterial Outer Membrane Proteins / Q000276:immunology; D018281:Cholangiocarcinoma / Q000453:epidemiology; D003429:Cross Reactions; D005260:Female; D016998:Helicobacter / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D012680:Sensitivity and Specificity; D013785:Thailand
chemical_list: D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D001425:Bacterial Outer Membrane Proteins